Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Naila Makhani, Christine Lebrun-Frenay, Aksel Siva, Veronika Shabanova, Evangeline Wassmer, Jonathan D Santoro, Sona Narula, J Nicholas Brenton, Soe Mar, Francoise Durand-Dubief, Helene Zephir, Guillaume Mathey, Juan I Rojas, Jerome de Seze, Silvia Tenembaum, Robert Thompson Stone, Olivier Casez, Clarisse Carra-Dallière, Rinze F Neuteboom, Nusrat Ahsan, Hugo A Arroyo, Philippe Cabre, Grace Gombolay, Matilde Inglese, Celine Louapre, Monica Margoni, Filipe Palavra, Daniela Pohl, Daniel S Reich, Aurélie Ruet, Eric Thouvenot, Niklas Timby, Mar Tintore, Ugur Uygunoglu, Wendy Vargas, Sunita Venkateswaran, Helene Verhelst, Ronny Wickstrom, Christina J Azevedo, Orhun Kantarci, Eugene D Shapiro, Darin T Okuda, Daniel Pelletier
BACKGROUND: Cerebrospinal fluid (CSF) and spinal MRIs are often obtained in children with the radiologically isolated syndrome (RIS) for diagnosis and prognosis. Factors affecting the frequency and timing of these tests are unknown. OBJECTIVE: To determine whether age or sex were associated with (1) having CSF or spinal MRI obtained or (2) the timing of these tests. METHODS: We analyzed children (≤ 18 y) with RIS enrolled in an international longitudinal study...
April 2, 2024: Journal of Neurology
#2
JOURNAL ARTICLE
Nail Benallegue, Fabien Rollot, Sandrine Wiertlewski, Romain Casey, Marc Debouverie, Anne Kerbrat, Jérôme De Seze, Jonathan Ciron, Aurelie Ruet, Pierre Labauge, Elisabeth Maillart, Helene Zephir, Caroline Papeix, Gilles Defer, Christine Lebrun-Frenay, Thibault Moreau, Eric Berger, Bruno Stankoff, Pierre Clavelou, Olivier Heinzlef, Jean Pelletier, Eric Thouvenot, Abdullatif Al Khedr, Bertrand Bourre, Olivier Casez, Philippe Cabre, Abir Wahab, Laurent Magy, Sandra Vukusic, David-Axel Laplaud
IMPORTANCE: Moderately effective therapies (METs) have been the main treatment in pediatric-onset multiple sclerosis (POMS) for years. Despite the expanding use of highly effective therapies (HETs), treatment strategies for POMS still lack consensus. OBJECTIVE: To assess the real-world association of HET as an index treatment compared with MET with disease activity. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study conducted from January 1, 2010, to December 8, 2022, until the last recorded visit...
February 12, 2024: JAMA Neurology
#3
JOURNAL ARTICLE
Caroline Pot
No abstract text is available yet for this article.
January 24, 2024: Revue Médicale Suisse
#4
JOURNAL ARTICLE
D Farge, G Pugnet, M Allez, C Castilla-Llorente, E Chatelus, P Cintas, C Faucher-Barbey, P Labauge, C Labeyrie, B Lioure, A Maria, D Michonneau, M Puyade, M Talouarn, L Terriou, X Treton, G Wojtasik, H Zephir, Z Marjanovic
Hematopoietic stem cell transplantation (HSCT) for severe ADs was developed over the past 25years and is now validated by national and international medical societies for severe early systemic sclerosis (SSc) and relapsing-remitting multiple sclerosis (MS) and available as part of routine care in accredited center. HSCT is also recommended, with varying levels of evidence, as an alternative treatment for several ADs, when refractory to conventional therapy, including specific cases of connective tissue diseases or vasculitis, inflammatory neurological diseases, and more rarely severe refractory Crohn's disease...
January 13, 2024: La Revue de Médecine Interne
#5
JOURNAL ARTICLE
Matthieu Perrenoud, Laurène Blosch, Renaud Du Pasquier, Caroline Pot
Cognitive disorders are present in 30 to 45% of relapsing-remitting forms of multiple sclerosis and in up to 50-75% of progressive forms. They bear a negative impact on the quality of life and predict an unfavorable disease progression. According to guidelines, screening based on objective measurement such as the Single Digit Modality Test (SDMT) should be performed at the time of diagnosis and then on an annual basis. Confirmation of diagnosis and management are performed in collaboration with neuropsychologists...
April 26, 2023: Revue Médicale Suisse
#6
JOURNAL ARTICLE
Clément Nougarède, Nathanaël Altmann
The French Multiple Sclerosis Association offers a psychological helpline for people with this disease, their families, friends and caregivers. Two clinical psychologists answer this toll-free number, which is accessible seven days a week at set times. They offer callers active listening and adapted support, particularly after the announcement of the medical diagnosis and/or in times of difficulty. The space thus created for discussion allows them to address emotional or personal aspects, material situations, as well as questions and problems associated with the experience of the disease...
March 2023: Soins; la Revue de Référence Infirmière
#7
JOURNAL ARTICLE
Fabienne Raynaud, Alexandra Viadere
The support provided at the Germaine-Revel medical center in the Rhône region involves assessing the patient as a whole, which is a key aspect of implementing personalized rehabilitation focused on one or more objectives. The team offers multidisciplinary and multimodal care, because the clinical symptoms of people with multiple sclerosis are very varied: they can include neuromotor, neurosensory, neurosensory and cognitive disorders, as well as bladder and bowel and genital disorders.
March 2023: Soins; la Revue de Référence Infirmière
#8
JOURNAL ARTICLE
Sophie Fantoni-Quinton
Becoming unfit for work or losing one's job because of multiple sclerosis is not inevitable. Many tools are available and occupational health professionals are now specifically mandated to support workers, whether or not they are employees, in maintaining their jobs, thanks in particular to the prevention of professional displacement unit, the recommendations of the French National Authority for Health and better coordination.
March 2023: Soins; la Revue de Référence Infirmière
#9
JOURNAL ARTICLE
Marie-Hélène Colpaert, Cathy Vanderveken
The MOTIV-SEP therapeutic education program for people with multiple sclerosis integrates the cognitive, emotional, behavioral and social components of therapeutic compliance. These components allow for an approach centered on the individual, in order to help him or her better support the important stage of starting treatment, but also to anticipate and reduce the obstacles to compliance.
March 2023: Soins; la Revue de Référence Infirmière
#10
JOURNAL ARTICLE
Thibault Moreau
The last thirty years have led to the introduction of treatments that reduce the frequency of relapses and slow the progression of multiple sclerosis. They must be prescribed early, chosen according to the form of the disease and actively monitored. Symptomatic treatments complete the treatment.
March 2023: Soins; la Revue de Référence Infirmière
#11
JOURNAL ARTICLE
Sophie Redaelli, Clémence Martineau, Fabienne Pelé, Alain Créange
The specialized nurse in MS is a new profession practiced in MS clinics and outpatients specialized coordination structures. She is part of a specialized multi-professional team. The nurse must master a broad knowledge of the disease and the treatments. Have skills in therapeutic education, communication and coordination. She has a detailed knowledge of the resources of the care offer. The MS nurse thus participates in the assessment of the patient's needs for the implementation of a personalized care plan combining response to medical, paramedical, psychological and social needs...
March 2023: Soins; la Revue de Référence Infirmière
#12
JOURNAL ARTICLE
Élisabeth Maillart
Multiple sclerosis (MS) is a chronic inflammatory pathology of the central nervous system, which affects young subjects. MS requires a multidisciplinary care coordinated between specialists and allied health professionals. A close collaboration is needed between the various praticians. The last decades have been marked by very significant progress, the diagnosis being established earlier and disease-modifying treatments introduced earlier, with the use of high-efficiency treatments. These therapeutic advances are exciting, however efforts are still needed to better understand the mechanisms of myelin repair and neurodegeneration...
March 2023: Soins; la Revue de Référence Infirmière
#13
EDITORIAL
Brigitte Hérisson
No abstract text is available yet for this article.
March 2023: Soins; la Revue de Référence Infirmière
#14
REVIEW
Mohammad Zubair Alam
Multiple Sclerosis (MS) is a complex autoimmune disease of central nervous system which is degenerative in nature usually appears between 20 - 40 years of age. The exact cause of MS is still not clearly known. Loss of myelin sheath and axonal damage are the main features of MS that causes induction of inflammatory process and blocks free conduction of impulses. Till date FDA has approved 18 drugs to treat or modify MS symptoms. These medicines are disease modifying in nature directed to prevent relapses or slow down the progression of disease...
March 22, 2023: Annales Pharmaceutiques Françaises
#15
JOURNAL ARTICLE
E Tan, N Turmel, J Kerdraon, A Guinet-Lacoste, J-G Prévinaire, E Castel-Lacanal, A Even, C Chesnel, C Hentzen, G Amarenco
BACKGROUND: Bowel symptoms are commonly experienced by patients with Multiple sclerosis (PwMS), but no specific questionnaire validated in this population allows a rigorous assessment. OBJECTIVE: Validation of a multidimensional questionnaire assessing bowel disorders in PwMS. METHODS: A prospective, multicenter study was conducted between April 2020 and April 2021. The STAR-Q (Symptoms' assessmenT of AnoRectal dysfunction Questionnaire), was built in 3 steps...
March 9, 2023: Progrès en Urologie
#16
JOURNAL ARTICLE
M A Pascual-Santiago, B P Burgos-Blasco, J E Enríquez-Fuentes, J I Fernandez-Vigo
Multiple sclerosis may present an increased risk for venous thromboembolism. Ophthalmological symptoms include loss of vision, visual field loss, changes in color vision, diplopia and nystagmus. First-line treatments for multiple sclerosis are beta-interferon, glatiramer acetate, dimethyl fumarate and teriflunomide. To the best of our knowledge, no ophthalmologic side effects have been reported with glatiramer acetate. We present a woman with multiple sclerosis on glatiramer acetate therapy with a central retinal vein occlusion in the absence of other risk factors...
February 9, 2023: Journal Français D'ophtalmologie
#17
JOURNAL ARTICLE
Antoine Gavoille, Fabien Rollot, Romain Casey, Marc Debouverie, Emmanuelle Le Page, Jonathan Ciron, Jerome De Seze, Aurélie Ruet, Elisabeth Maillart, Pierre Labauge, Helene Zephir, Caroline Papeix, Gilles Defer, Christine Lebrun-Frenay, Thibault Moreau, David Axel Laplaud, Eric Berger, Bruno Stankoff, Pierre Clavelou, Eric Thouvenot, Olivier Heinzlef, Jean Pelletier, Abdullatif Al Khedr, Olivier Casez, Bertrand Bourre, Philippe Cabre, Abir Wahab, Laurent Magy, Jean-Philippe Camdessanche, Aude Maurousset, Solène Moulin, Nasr Haifa Ben, Dalia Dimitri Boulos, Karolina Hankiewicz, Jean-Philippe Neau, Corinne Pottier, Chantal Nifle, Muriel Rabilloud, Fabien Subtil, Sandra Vukusic
BACKGROUND AND OBJECTIVES: The question of the long-term safety of pregnancy is a major concern in multiple sclerosis (MS) patients, but its study is biased by reverse causation (women with higher disability are less likely to experience pregnancy). Using a causal inference approach, we aimed to estimate the unbiased long-term effects of pregnancy on disability and relapse risk in MS patients, and secondarily the short-term effects (during the per-partum and post-partum years) and delayed effects (occurring beyond one year after delivery)...
December 23, 2022: Neurology
#18
JOURNAL ARTICLE
C Orssaud
The diagnosis of Leber hereditary optic neuropathy is suspected in the siblings of an affected person that complains of a decrease in visual acuity. It can also be suspected in a young subject, especially a male, with no medical history that presents with an optic neuropathy. Leber hereditary optic neuropathy is a diagnosis of exclusion. The search for differential diagnoses is essential in all cases, even when a mutation of the mitochondrial DNA was found in the patient of in a healthy carrier maternal relative...
November 2022: Journal Français D'ophtalmologie
#19
JOURNAL ARTICLE
Sarah Wilson, Floriane Calocer, Fabien Rollot, Mathieu Fauvernier, Laurent Remontet, Laure Tron, Sandra Vukusic, Emmanuelle Le Page, Marc Debouverie, Jonathan Ciron, Aurélie Ruet, Jérôme De Sèze, Hélène Zephir, Thibault Moreau, Christine Lebrun-Frénay, David-Axel Laplaud, Pierre Clavelou, Pierre Labauge, Eric Berger, Jean Pelletier, Olivier Heinzlef, Eric Thouvenot, Jean Philippe Camdessanché, Emmanuelle Leray, Olivier Dejardin, Gilles Defer
BACKGROUND: The effects of socio-economic status on mortality in patients with multiple sclerosis is not well known. The objective was to examine mortality due to multiple sclerosis according to socio-economic status. METHODS: A retrospective observational cohort design was used with recruitment from 18 French multiple sclerosis expert centers participating in the Observatoire Français de la Sclérose en Plaques. All patients lived in metropolitan France and had a definite or probable diagnosis of multiple sclerosis according to either Poser or McDonald criteria with an onset of disease between 1960 and 2015...
January 2023: The Lancet regional health. Europe
#20
MULTICENTER STUDY
Michael Levraut, Sabine Laurent-Chabalier, Xavier Ayrignac, Kévin Bigaut, Manon Rival, Sanae Squalli, Hélène Zéphir, Tifanie Alberto, Jean-David Pekar, Jonathan Ciron, Damien Biotti, Bénédicte Puissant-Lubrano, Jean-Philippe Camdessanché, Yannick Tholance, Olivier Casez, Bertrand Toussaint, Jeanne Marion, Thibault Moreau, Daniela Lakomy, Audrey Thomasset, Elisabeth Maillart, Delphine Sterlin, Aude Maurousset, Auriane Rocher, David Axel Laplaud, Edith Bigot-Corbel, Pierre-Olivier Bertho, Jean Pelletier, Joseph Boucraut, Pierre Labauge, Thierry Vincent, Jérôme De Sèze, Isabelle Jahn, Barbara Seitz-Polski, Eric Thouvenot, Christine Lebrun-Frenay
BACKGROUND AND OBJECTIVES: Kappa free light chains (KFLC) seem to efficiently diagnose MS. However, extensive cohort studies are lacking to establish consensus cut-offs, notably to rule out non-MS autoimmune CNS disorders. Our objectives were to (1) determine diagnostic performances of CSF KFLC, KFLC index, and KFLC intrathecal fraction (IF) threshold values that allow us to separate MS from different CNS disorder control populations and compare them with oligoclonal bands' (OCB) performances and (2) to identify independent factors associated with KFLC quantification in MS...
January 2023: Neurology® Neuroimmunology & Neuroinflammation
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
